POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
J. Cortés-Hernández, S. Ignatenko, A. Gordienko, N. Agmon-Levin, P. Narongroeknawin, K. Romanowska -Prochnicka, N. Shen, H. Ciferská, M. Kodera, J. C. C. Wei, P. Leszczynski, J. L. Lan, R. Wojciechowski, T. Tarr, E. Vishneva, Y. H. Chen, Y. Kaneko, S. Finzel, A. Hoi, M. Okada, A. Koolvisoot, S. S. Lee, L. Dai, H. Kaneko, B. Rojkovich, L. Sun, E. Zotkin, B. Magallares, T. Sengupta, C. Sips, S. Oliver
Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1) 275-276; DOI: 10.1136/annrheumdis-2023-eular.3110